1. Hot Topics in Lymphoma Supportive Care

2. Program Goal

3. Program Overview

4. Lenalidomide

5. Lenalidomide Toxicities

6. Lenalidomide-Associated Tumor Flare Reaction

7. Management of Tumor Flare Reaction

8. Bendamustine

9. Bendamustine-Associated Toxicities

10. Skin Reactions

11. Managing Skin Reactions

12. PI3K Delta and BTK Inhibition in B-Cell Neoplasms

13. B-Cell Receptor Pathway Inhibitors: Peripheral Lymphocytosis

14. Ibrutinib Monotherapy in Relapsed/Refractory CLL/SLL

15. Ibrutinib Monotherapy in Relapsed/Refractory MCL

16. Idelalisib (GS-1101, CAL-101)

17. Brentuximab Vedotin

18. Brentuximab Vedotin Toxicities

20. Delayed-Onset Neutropenia After Rituximab

21. Rituximab-Associated Hypogammaglobulinemia

22. Rituximab-Associated Hypogammaglobulinemia (cont)

23. Hepatitis B Viral Reactivation

25. PML: Viral Reactivation of JC Virus

26. PML: Findings of the RADAR Project

27. Causes of PML

28. Diagnosing PML

29. Tumor Lysis Syndrome

30. Definition of Clinical TLS

31. Management of TLS

32. Hyperuricemia: Allopurinol

33. Hyperuricemia: Rasburicase

34. Limitations of Rasburicase

35. Cancer-Related Fatigue

36. Management of Cancer-Related Fatigue

37. Reporting Adverse Effects

38. Abbreviations

39. Abbreviations (cont)

40. Abbreviations (cont)

41. References

42. References (cont)

43. References (cont)

44. References (cont)

45. References (cont)

46. References (cont)

47. References (cont)

48. References (cont)

49. References (cont)

50. References (cont)